Ghent University Academic Bibliography

Your filters: cql: author="Monif, Mastura" or (type any "bookEditor issueEditor" and editor="Monif, Mastura")

Add to list
- Journal Article
- A1
- open access
Progression independent of relapse activity and relapse-associated worsening in seronegative NMOSD : an international cohort study

Pakeeran Siriratnam, Saif Huda, Anneke Van der Walt, Paul Sanfilippo, Sifat Sharmin, Yi Chao Foong, Wei Zhen Yeh, Chao Zhu, Samia J. Khoury, Tunde Csepany, et al.

(2025) JOURNAL OF NEUROLOGY. 272(5).
Add to list
- Journal Article
- A1
- open access
Predictors of relapse risk and treatment response in AQP4-IgG positive and seronegative NMOSD : a multicentre study

Pakeeran Siriratnam, Paul Sanfilippo, Anneke van der Walt, Sifat Sharmin, Yi Chao Foong, Wei Zhen Yeh, Chao Zhu, Samia Joseph Khoury, Tunde Csepany, Barbara Willekens, et al.

(2025) JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. 96(4). p.361-369
Add to list
- Journal Article
- A2
- open access
Persistent progression independent of relapse activity in multiple sclerosis

Chao Zhu, Zhen Zhou, Tomas Kalincik, Izanne Roos, Katherine Buzzard, Olga Skibina, Raed Alroughani, Jens Kuhle, Marc Girard, Pierre Grammond, et al.

(2025) BRAIN COMMUNICATIONS. 7(5).
Add to list
- Journal Article
- A1
- open access
The impact of COVID-19 infection on multiple sclerosis disease course across 12 countries : a propensity-score-matched cohort study

David Levitz, Yi Chao Foong, Paul Sanfilippo, Tim Spelman, Louise Rath, Angie Roldan, Anoushka Lal, Mastura Monif, Vilija Jokubaitis, Serkan Ozakbas, et al.

(2024) THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS. 17.
Add to list
- Journal Article
- A1
- open access
Comparison between dimethyl fumarate, fingolimod, and ocrelizumab after natalizumab cessation

Chao Zhu, Tomas Kalincik, Dana Horakova, Zhen Zhou, Katherine Buzzard, Olga Skibina, Raed Alroughani, Guillermo Izquierdo, Sara Eichau, Jens Kuhle, et al.

(2023) JAMA NEUROLOGY. 80(7). p.739-748
Add to list
- Journal Article
- A1
- open access
Rituximab vs ocrelizumab in relapsing-remitting multiple sclerosis

Izanne Roos, Stella Hughes, Gavin McDonnell, Charles B. Malpas, Sifat Sharmin, Cavit Boz, Raed Alroughani, Serkan Ozakbas, Katherine Buzzard, Olga Skibina, et al.

(2023) JAMA NEUROLOGY. 80(8). p.789-797
Add to list
- Journal Article
- A1
- open access
Comparative effectiveness of autologous hematopoietic stem cell transplant vs fingolimod, natalizumab, and ocrelizumab in highly active relapsing-remitting multiple sclerosis

Tomas Kalincik, Sifat Sharmin, Izanne Roos, Mark S. Freedman, Harold Atkins, Joachim Burman, Jennifer Massey, Ian Sutton, Barbara Withers, Richard Macdonell, et al.

(2023) JAMA NEUROLOGY. 80(7). p.702-713
Add to list
Prediction of multiple sclerosis outcomes when switching to ocrelizumab

Michael Zhong, Anneke van der Walt, Jim Stankovich, Tomas Kalincik, Katherine Buzzard, Olga Skibina, Cavit Boz, Suzanne Hodgkinson, Mark Slee, Jeannette Lechner-Scott, et al.

(2022) MULTIPLE SCLEROSIS JOURNAL. 28(6). p.958-969

Academic Bibliography

Progression independent of relapse activity and relapse-associated worsening in seronegative NMOSD : an international cohort study

Predictors of relapse risk and treatment response in AQP4-IgG positive and seronegative NMOSD : a multicentre study

Persistent progression independent of relapse activity in multiple sclerosis

The impact of COVID-19 infection on multiple sclerosis disease course across 12 countries : a propensity-score-matched cohort study

Comparison between dimethyl fumarate, fingolimod, and ocrelizumab after natalizumab cessation

Rituximab vs ocrelizumab in relapsing-remitting multiple sclerosis

Comparative effectiveness of autologous hematopoietic stem cell transplant vs fingolimod, natalizumab, and ocrelizumab in highly active relapsing-remitting multiple sclerosis

Prediction of multiple sclerosis outcomes when switching to ocrelizumab

Contents

Support

Contact